Skip to main content

Table 1 Baseline clinical characteristics of the study population

From: Prognostic impact of estimated remnant-like particle cholesterol in patients with differing glycometabolic status: an observational cohort study from China

  Total population, n = 2419 Without event, n = 1965 With event, n = 454 P
Age, years 60.08 ± 8.97 59.60 ± 8.72 62.16 ± 9.70 <  0.001
Male, n (%) 1737 (71.8) 1422 (72.4) 315 (69.4) 0.203
BMI, kg/m2 26.21 ± 3.45 26.13 ± 3.40 26.55 ± 3.61 0.019
Heart rate, bpm 69.77 ± 10.15 69.44 ± 10.00 71.17 ± 10.69 0.002
SBP, mmHg 130.30 ± 16.52 129.80 ± 15.99 132.44 ± 18.50 0.005
DBP, mmHg 77.05 ± 9.90 77.00 ± 9.68 77.25 ± 10.80 0.661
Smoking, n (%) 1381 (57.1) 1127 (57.4) 254 (55.9) 0.585
Drinking, n (%) 562 (23.2) 468 (23.8) 94 (20.7) 0.157
Family history of CAD, n (%) 254 (10.5) 203 (10.3) 51 (11.2) 0.572
Medical history, n (%)
 Hypertension 1511 (62.5) 1210 (61.6) 301 (66.3) 0.061
 Prior MI 527 (21.8) 348 (17.7) 179 (39.4) <  0.001
 Prior PCI 414 (17.1) 280 (14.2) 134 (29.5) <  0.001
 Prior CABG 55 (2.3) 23 (1.2) 32 (7.0) <  0.001
 Prior stroke 281 (11.6) 204 (10.4) 77 (17.0) <  0.001
 Prior PAD 84 (3.5) 63 (3.2) 21 (4.6) 0.137
Glycometabolic status
 Non-diabetes 926 (38.3) 829 (42.2) 97 (21.4) <  0.001
 Pre-diabetes 645 (26.7) 531 (27.0) 114 (25.1) 0.406
 Diabetes 848 (35.1) 605 (30.8) 243 (53.5) <  0.001
Laboratory results
 TGs, mmol/L 1.84 ± 1.32 1.69 ± 1.05 2.47 ± 2.00 <  0.001
 TC, mmol/L 4.17 ± 1.06 4.14 ± 1.05 4.33 ± 1.07 0.001
 LDL-C, mmol/L 2.50 ± 0.88 2.50 ± 0.89 2.50 ± 0.85 0.962
 HDL-C, mmol/L 0.98 ± 0.23 0.99 ± 0.24 0.92 ± 0.21 <  0.001
 Estimated RLP-C, mmol/L 0.69 ± 0.42 0.65 ± 0.35 0.90 ± 0.61 <  0.001
 hs-CRP, mg/L 1.29 (0.58, 3.31) 1.22 (0.53, 3.06) 1.87 (0.77, 4.29) <  0.001
 Creatinine, μmol/L 76.00 ± 16.95 75.68 ± 16.49 77.42 ± 18.76 0.048
 eGFR, ml/(min*1.73m2) 93.49 ± 20.36 94.09 ± 20.11 90.91 ± 21.22 0.003
 Uric acid, μmol/L 346.22 ± 82.64 346.45 ± 81.45 345.21 ± 87.69 0.774
 FBG, mmol/L 6.20 ± 1.94 6.01 ± 1.71 7.03 ± 2.57 <  0.001
 HbA1c, % 5.90 (5.50, 6.60) 5.80 (5.50, 6.40) 6.40 (5.80, 8.00) <  0.001
 LVEF, % 65.00 (60.00, 68.00) 65.00 (61.00, 69.00) 63.00 (57.00, 67.00) <  0.001
Initial diagnosis, n (%)     0.001
 UA 2018 (83.4) 1662 (84.6) 356 (78.4)  
 NSTEMI 401 (16.6) 303 (15.4) 98 (21.6)  
Medical treatment, n (%)
 ACEI 734 (30.3) 577 (29.4) 157 (34.6) 0.029
 ARB 948 (39.2) 753 (38.3) 195 (43.0) 0.068
 Aspirin 2417 (99.9) 1963 (99.9) 454 (100.0) 0.496
 Clopidogrel 2415 (99.8) 1963 (99.9) 452 (99.6) 0.109
 β-Blocker 2199 (90.9) 1780 (90.6) 419 (92.3) 0.255
 Statins 2366 (97.8) 1922 (97.8) 444 (97.8) 0.985
 Oral hypoglycemic agents 437 (18.1) 314 (16.0) 123 (27.1) <  0.001
 Insulin 232 (9.6) 154 (7.8) 78 (17.2) <  0.001
Angiographic data, n (%)
 Left main disease 110 (4.5) 64 (3.3) 46 (10.1) <  0.001
 Multi-vessel disease 1631 (67.4) 1225 (62.3) 406 (89.4) <  0.001
 Chronic total occlusion 345 (14.3) 202 (10.3) 143 (31.5) <  0.001
 Diffuse lesion 605 (25.0) 431 (21.9) 174 (38.3) <  0.001
 Bifurcation lesion 492 (20.3) 368 (18.7) 124 (27.3) <  0.001
Number of stents 1.96 ± 1.29 1.87 ± 1.14 2.33 ± 1.76 <  0.001
  1. Bold values indicate statistically significant associations
  2. BMI Body mass index, SBP Systolic blood pressure, DBP Diastolic blood pressure, CAD Coronary artery disease, MI Myocardial infarction, PCI Percutaneous coronary intervention, CABG Coronary artery bypass grafting, PAD Peripheral arterial disease, TGs Triglycerides, TC Total cholesterol, LDL-C Low-density lipoprotein cholesterol, HDL-C High-density lipoprotein cholesterol, RLP-C Remnant-like particle cholesterol, hs-CRP High-sensitivity C-reactive protein, eGFR Estimated glomerular filtration rate, FBG Fasting blood glucose, HbA1c Glycosylated hemoglobin A1c, LVEF Left ventricular ejection fraction, UA Unstable angina, NSTEMI Non-ST-segment elevation myocardial infarction, ACEI Angiotensin-converting enzyme inhibitor, ARB Angiotensin receptor blocker
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X